➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Merck
Mallinckrodt
McKesson
Dow

Last Updated: June 18, 2021

DrugPatentWatch Database Preview

NOURIANZ Drug Profile


Email this page to a colleague

« Back to Dashboard

When do Nourianz patents expire, and what generic alternatives are available?

Nourianz is a drug marketed by Kyowa Kirin and is included in one NDA. There are four patents protecting this drug.

This drug has sixty-three patent family members in eighteen countries.

The generic ingredient in NOURIANZ is istradefylline. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the istradefylline profile page.

DrugPatentWatch® Generic Entry Outlook for Nourianz

Nourianz will be eligible for patent challenges on August 27, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 13, 2024. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try Before You Buy

Summary for NOURIANZ
International Patents:63
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 78
Patent Applications: 411
Drug Prices: Drug price information for NOURIANZ
What excipients (inactive ingredients) are in NOURIANZ?NOURIANZ excipients list
DailyMed Link:NOURIANZ at DailyMed
Drug patent expirations by year for NOURIANZ
Drug Prices for NOURIANZ

See drug prices for NOURIANZ

DrugPatentWatch® Estimated Generic Entry Opportunity Date for NOURIANZ
Generic Entry Date for NOURIANZ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for NOURIANZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-001 Aug 27, 2019 RX Yes No   Try Before You Buy   Try Before You Buy   Try Before You Buy
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-002 Aug 27, 2019 RX Yes Yes   Try Before You Buy   Try Before You Buy   Try Before You Buy
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-001 Aug 27, 2019 RX Yes No   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-002 Aug 27, 2019 RX Yes Yes   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-001 Aug 27, 2019 RX Yes No   Try Before You Buy   Try Before You Buy   Try Before You Buy
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-001 Aug 27, 2019 RX Yes No   Try Before You Buy   Try Before You Buy Y Y   Try Before You Buy
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-002 Aug 27, 2019 RX Yes Yes   Try Before You Buy   Try Before You Buy   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NOURIANZ

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 03063876   Try Before You Buy
European Patent Office 2044940   Try Before You Buy
South Korea 20150080013   Try Before You Buy
South Korea 101098209   Try Before You Buy
Brazil 0306919   Try Before You Buy
South Korea 20120103740   Try Before You Buy
Japan 2009067807   Try Before You Buy
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Boehringer Ingelheim
AstraZeneca
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.